Streptomyces Derivatives Market
Number of pages: 100 | Report Format: PDF | Published date: June 15, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
1.8% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drugs, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global streptomyces derivatives market is expected to grow at a revenue CAGR of 1.8% from 2023 to 2031.
Streptomyces Derivatives Market Fundamentals
Streptomyces derivatives refer to compounds or products derived from the microorganism Streptomyces. Streptomyces is a genus of bacteria that belongs to the Actinobacteria phylum. It is known for its ability to produce a wide range of bioactive compounds, including antibiotics, enzymes, and other secondary metabolites. Streptomyces bacteria are commonly found in soil and are known for their filamentous growth and complex life cycle. They produce numerous bioactive compounds to defend against other microorganisms in their environment. Streptomyces derivatives are extensively used in various industries, particularly in pharmaceuticals and biotechnology. In addition, Streptomyces derivatives have agricultural applications as biocontrol agents, helping to combat plant diseases and improve crop yields. They are used as natural alternatives to chemical pesticides, promoting sustainable and environmentally friendly agriculture.
Streptomyces Derivatives Market Dynamics
Streptomyces derivatives are a major source of antibiotics. With the rise in bacterial infections and the emergence of antibiotic-resistant strains, there is a growing need for new and effective antibiotics. Streptomyces derivatives continue to be a valuable resource for the development of novel antibiotics, driving the streptomyces derivatives market demand. According to ReAct (a SIDA-funded organization), a bacterial infection is responsible for 7.7 million deaths worldwide. This accounts for 13.6% of all deaths worldwide or one in every eight. The pharmaceutical sector is growing globally, driven by factors such as population growth, increasing healthcare spending, and advancements in medical research. Streptomyces derivatives are widely used in the production of pharmaceutical drugs, including antibiotics, antifungal agents, and other bioactive compounds, which is contributing to the growth of the streptomyces derivatives market. Streptomyces derivatives have gained importance in agriculture due to their biocontrol properties. With a growing focus on sustainable agricultural practices and reducing chemical pesticides, the demand for streptomyces derivatives as natural biocontrol agents is increasing. Streptomyces derivatives serve as a valuable enzyme source with diverse applications across multiple industries, including food and beverage, biofuel production, and industrial processes. Consequently, the market for streptomyces derivatives is fueled by the increasing need for enzyme-based solutions in various business sectors. Advancements in biotechnology and genetic engineering techniques have opened new avenues for developing and optimizing streptomyces derivatives. Researchers are using tools like genome sequencing, gene editing, and synthetic biology to enhance the production of desired compounds, improve yields, and modify the properties of streptomyces derivatives.
However, the rise of antibiotic-resistant bacteria poses a significant challenge for the antibiotic market, including streptomyces derivatives. The increasing prevalence of multidrug-resistant strains reduces the effectiveness of existing antibiotics, restricting the growth of streptomyces derivatives. The development and commercialization of streptomyces derivatives, especially pharmaceutical products, are subject to stringent regulatory requirements. Obtaining regulatory approvals and ensuring compliance with safety and efficacy standards are also hindering the streptomyces derivatives market growth.
Streptomyces Derivatives Market Ecosystem
The global streptomyces derivatives market is analyzed from three perspectives: drugs, indication, and region.
Streptomyces Derivatives Market by Drugs
Based on the drugs, the global streptomyces derivatives market is segmented into seromycin, capreomycin, streptomycin, spectinomycin, tetracycline, and others.
The streptomycin segment accounted for the largest revenue share of the streptomyces derivatives market in 2022. Streptomycin was one of the first antibiotics to be discovered and commercially produced from Streptomyces. Streptomycin's early success and effectiveness established its prominence in the field of antibiotics derived from Streptomyces. Streptomycin exhibits a broad spectrum of activity against a wide range of bacteria, including both Gram-positive and Gram-negative strains. This broad coverage makes it effective against various types of infections caused by susceptible bacteria, contributing to its widespread use and growth within the Streptomyces derivatives market. Streptomycin has been critical in treating several infectious diseases, including tuberculosis, tularemia, and plague. Its importance in managing these serious conditions has solidified its position as a prominent antibiotic. Despite the emergence of newer antibiotics, Streptomycin continues to be prescribed and used in specific clinical scenarios, especially for infections caused by drug-resistant bacteria. It remains a valuable option in cases where alternative antibiotics may be less effective.
The tetracycline segment accounted for a considerable streptomyces derivatives market share in 2022. Tetracycline is a broad-spectrum antibiotic derived from Streptomyces that exhibits activity against a wide range of bacteria, including both Gram-positive and Gram-negative strains. Its effectiveness against various types of infections, including respiratory tract infections, urinary tract infections, and skin infections, contributes to its widespread use and revenue generation in the market. According to the National Center For Biotechnology Information, the absolute number of UTI cases grew by 60.40% between 1990 and 2019, from 252.25 million to 404.61 million. Tetracycline has been used in clinical practice for many years, establishing a solid reputation and physician familiarity. Its long-standing presence in the market has resulted in a substantial patient base and continued demand, contributing to its revenue share. Tetracycline is known for its relatively low cost compared to some newer antibiotics. This cost-effectiveness makes it attractive, particularly in regions or healthcare systems with limited resources. The affordability and accessibility of Tetracycline have supported its revenue share in the Streptomyces derivatives market. In addition to its antibiotic properties, tetracycline has been studied for its potential therapeutic applications beyond infectious diseases. It has demonstrated promising effects in various non-infectious conditions, including anti-inflammatory, anticancer, and bone-regenerative properties. Ongoing research exploring these novel applications may further expand the revenue opportunities for tetracycline in the future. While antibiotic resistance is a growing concern, tetracycline has maintained a relatively favorable resistance profile compared to other antibiotics. This aspect contributes to its continued use and revenue generation, as it remains effective against a significant number of susceptible bacterial strains.
Streptomyces Derivatives Market by Indication
Based on the indications, the global streptomyces derivatives market is segmented into tuberculosis, plague, brucellosis, endocarditis, rabbit fever, and others.
The tuberculosis segment accounted for the highest streptomyces derivatives market share. Tuberculosis (TB) is a global health concern, with a significant disease burden in many parts of the world. It is caused by the bacterium Mycobacterium tuberculosis, and Streptomyces derivatives have played a crucial role in the development of effective treatments for TB. The high prevalence of TB drives the demand for Streptomyces-derived drugs within this segment. According to the WHO, an estimated 10.6 million individuals globally were infected by tuberculosis (TB) in 2021. Six million males, 3.4 million women, and 1.2 million children make up the population. Similarly, it is estimated to have increased by 3.6% between 2020 and 2021. Streptomyces derivatives have been a prolific source of antibiotics, many of which are highly effective against Mycobacterium tuberculosis. These drugs have proven efficacy against TB and are integral to standard TB treatment regimens. TB treatment typically involves a prolonged duration of therapy, often lasting several months. This extended treatment period increases the demand for TB drugs and contributes to the revenue growth of the TB segment within the Streptomyces derivatives market. The emergence of multi-drug resistant strains of Mycobacterium tuberculosis, known as MDR-TB, has further fueled the demand for Streptomyces-derived drugs. Streptomyces derivatives have been instrumental in developing second-line drugs used to combat MDR-TB, such as injectable agents like Amikacin and Capreomycin. The global health community, along with organizations such as the WHO, has prioritized efforts to combat TB. Initiatives and funding for TB prevention, diagnosis, and treatment have significantly contributed to the market dominance of the TB segment.
Streptomyces Derivatives Market by Region
Geographically, the global streptomyces derivatives market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest streptomyces derivatives market size in terms of revenue generation accounting for around 33.6% share of the market. North America has a significant demand for pharmaceutical products, including antibiotics and other therapeutic agents derived from Streptomyces. The region's large population, high prevalence of certain diseases, and advanced healthcare infrastructure contribute to the increased demand for Streptomyces derivatives in the pharmaceutical sector. North America is known for its advanced research and development capabilities and technological advancements. These advancements enable the discovery, development, and production of novel Streptomyces-derived compounds and pharmaceutical products. North America has well-established regulatory frameworks for pharmaceutical products, ensuring safety, efficacy, and quality. The region's robust regulatory environment provides a conducive ecosystem for the development, approval, and commercialization of Streptomyces derivatives. North America has a strong network of academic institutions, research organizations, and pharmaceutical companies actively engaged in collaborative research initiatives. These collaborations foster knowledge sharing, accelerate the discovery of novel Streptomyces-derived compounds, and facilitate their translation into marketable products.
The Asia Pacific region is expected to register the fastest growth rate during the forecast period for 2023 to 2031. The Asia Pacific region is home to a significant and rapidly growing population. The increasing population creates a higher demand for healthcare products, including pharmaceuticals derived from Streptomyces. The rising prevalence of infectious diseases in densely populated areas drives the demand for Streptomyces derivatives in the region. The Asia Pacific region is known to have a high burden of infectious diseases such as tuberculosis, malaria, and respiratory tract infections. Streptomyces derivatives, particularly antibiotics, play a critical role in the treatment and management of these diseases. According to the WHO, in 2021, the largest number of new TB cases occurred in the South-East Asian Region, with 46% of all cases. Many countries in the Asia Pacific region, such as India and China, have well-established pharmaceutical manufacturing capabilities. These countries are major producers and exporters of generic drugs, including those derived from Streptomyces. The Asia Pacific region has been experiencing a steady increase in healthcare expenditure. Governments and private sectors are investing more in healthcare infrastructure, research and development, and access to healthcare services.
Streptomyces Derivatives Market Competitive Landscape
The prominent players operating in the global streptomyces derivativesmarket are:
Streptomyces derivatives refer to compounds or products derived from the microorganism Streptomyces. Streptomyces is a genus of bacteria that belongs to the Actinobacteria phylum.
Asia Pacific is the key growth region in the global market during the forecast period from 2023 to 2031.
The prominent players operating in the global streptomyces derivatives market are Eli Lilly and Company, Pfizer Inc., Novartis AG, Merck & Co., Inc., and AbbVie Inc.
Strategic collaborations and partnerships with academic institutions, research organizations, and other industry players are commonly pursued by market players. These collaborations facilitate knowledge sharing, access to specialized expertise, and sharing of resources, enabling faster development and commercialization of Streptomyces derivatives.
The global streptomyces derivatives market growth is estimated to grow at a revenue CAGR of 1.8% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain